Advertisement

Liver Cancers pp 199-212 | Cite as

Cholangiocarcinoma: From Mechanisms to Management

  • Leonard M. Quinn
  • Nicholas Bird
  • Robert Jones
  • David Vass
  • Hassan MalikEmail author
Chapter

Abstract

Cholangiocarcinoma represents a spectrum of biliary tract adenocarcinoma, including intrahepatic and extrahepatic disease. A rare malignancy with recognized risk factors, the genomic spectra of the disease, is still being defined. Symptomatically silent in the early stages, cholangiocarcinoma manifests a very poor prognosis with many patients having advanced disease at presentation. Surgery represents the only curative approach. Unfortunately, only a minority of patients have resectable disease. Both resected and non-resected patients are offered a variety of chemotherapy regimens with randomized clinical trials having recently reported. Preoperative (neoadjuvant) chemotherapy and orthotopic liver transplantation are not standard treatment protocol at the current time. We conclude this chapter with a discussion of ongoing and future research.

Keywords

Intrahepatic cholangiocarcinoma Perihilar cholangiocarcinoma Distal cholangiocarcinoma Biliary tract cancer 

References

  1. 1.
    Nagorney DM, Pawlik TM, Chun YS, et al. Perihilar bile ducts. In: Amin MB, editor. AJCC cancer staging manual. 8th ed. Chicago: AJCC; 2017. p. 312.Google Scholar
  2. 2.
    DeOliveira ML, Cunningham SC, Cameron JL, et al. Cholangiocarcinoma: thirty-one-year experience with 564 patients at a single institution. Ann Surg. 2007;245(5):755.PubMedPubMedCentralCrossRefGoogle Scholar
  3. 3.
    Bismuth H, Nakache R, Diamond T. Management strategies in resection for hilar cholangiocarcinoma. Ann Surg. 1992;215(1):31.PubMedPubMedCentralCrossRefGoogle Scholar
  4. 4.
    Edge SB, Byrd DR, Compton CC, et al., editors. American Joint Committee on Cancer staging manual. 7th ed. New York: Springer; 2010. p. 201.Google Scholar
  5. 5.
    Janargin WR, Fong Y, DeMatteo RP, et al. Staging, resectability and outcome in 225 patients with hilar cholangiocarcinoma. Ann Surg. 2001;234(4):507–17.CrossRefGoogle Scholar
  6. 6.
    Vauthey JN, Blumgart LH. Recent advances in the management of cholangiocarcinomas. Semin Liver Dis. 1994;14(2):109.PubMedCrossRefGoogle Scholar
  7. 7.
    Shaib YH, El-Serag HB, Davila JA, Morgan R, McGlynn KA. Risk factors of intrahepatic cholangiocarcinoma in the United States: a case-control study. Gastroenterology. 2005;128(3):620.PubMedCrossRefGoogle Scholar
  8. 8.
    Henson DE, Albores-Saavedra J, Corle D. Carcinoma of the extrahepatic bile ducts. Histologic types, stage of disease, grade, and survival rates. Cancer. 1992;70(6):1498.PubMedCrossRefGoogle Scholar
  9. 9.
    Chapman RW. Risk factors for biliary tract carcinogenesis. Ann Oncol. 1999;10(Suppl 4):308.PubMedCrossRefGoogle Scholar
  10. 10.
    Bergquist A, Ekbom A, Olsson R, et al. Hepatic and extrahepatic malignancies in primary sclerosing cholangitis. J Hepatol. 2002;36(3):321.PubMedCrossRefGoogle Scholar
  11. 11.
    Lipsett PA, Pitt HA, Colombani PM, Boitnott JK, Cameron JL. Choledochal cyst disease. A changing pattern of presentation. Ann Surg. 1994;220(5):644.PubMedPubMedCentralCrossRefGoogle Scholar
  12. 12.
    Hsing AW, Gao YT, Han TQ, et al. Gallstones and the risk of biliary tract cancer: a population-based study in China. Br J Cancer. 2007;97(11):1577.PubMedPubMedCentralCrossRefGoogle Scholar
  13. 13.
    Mahale P, Torres HA, Kramer JR, Hwang LY, Li R, Brown EL, Engels EA. Hepatitis C virus infection and the risk of cancer among elderly US adults: a registry-based case-control study. Cancer. 2017;123(7):1202. Epub 2017 Jan 24.PubMedCrossRefGoogle Scholar
  14. 14.
    Watanapa P, Watanapa WB. Liver fluke-associated cholangiocarcinoma. Br J Surg. 2002;89(8):962.PubMedCrossRefGoogle Scholar
  15. 15.
    Cardinale V, Carpino G, Reid L, Gaudio E, Alvaro D. Multiple cells of origin in cholangiocarcinoma underlie biological, epidemiological and clinical heterogeneity. World J Gastrointest Oncol. 2012;4:94–102.PubMedPubMedCentralCrossRefGoogle Scholar
  16. 16.
    Cardinale V, et al. Profiles of cancer stem cell subpopulations in cholangiocarcinomas. Am J Pathol. 2015;185:1724–39.PubMedPubMedCentralCrossRefGoogle Scholar
  17. 17.
    Nakanishi Y, Zen Y, Kondo S, Itoh T, Itatsu K, Nakanuma Y. Expression of cell cycle-related molecules in biliary premalignant lesions: biliary intraepithelial neoplasia and biliary intraductal papillary neoplasm. Hum Pathol. 2008;39(8):1153.PubMedCrossRefGoogle Scholar
  18. 18.
    Isa T, Tomita S, Nakachi A, Miyazato H, Shimoji H, Kusano T, Muto Y, Furukawa M. Analysis of microsatellite instability, K-ras gene mutation and p53 protein overexpression in intrahepatic cholangiocarcinoma. Hepatogastroenterology. 2002;49(45):604.PubMedGoogle Scholar
  19. 19.
    Arai Y, et al. Fibroblast growth factor receptor 2 tyrosine kinase fusions define a unique molecular subtype of cholangiocarcinoma. Hepatology. 2014;59:1427–34.PubMedCrossRefGoogle Scholar
  20. 20.
    Borger DR, Tanabe KK, Fan KC, et al. Frequent mutation of isocitrate dehydrogenase (IDH)1 and IDH2 in cholangiocarcinoma identified through broad-based tumor genotyping. Oncologist. 2012;17(1):72–9. Epub 2011 Dec 16.PubMedCrossRefGoogle Scholar
  21. 21.
    Yoshikawa D, et al. Clinicopathological and prognostic significance of EGFR, VEGF and HER2 expression in cholangiocarcinoma. Br J Cancer. 2008;98:418–25.PubMedCrossRefGoogle Scholar
  22. 22.
    Alvaro D, et al. Estrogens and insulin-like growth factor 1 modulate neoplastic cell growth in human cholangiocarcinoma. Am J Pathol. 2006;169:877–88.PubMedPubMedCentralCrossRefGoogle Scholar
  23. 23.
    Webhe H, Henson R, Meng F, Mize-Berge J, Patel T. Interleukin-6 contributes to growth in cholangiocarcinoma cells by aberrant promoter methylation and gene expression. Cancer Res. 2006;66:10517–24.CrossRefGoogle Scholar
  24. 24.
    Sato Y, et al. Epithelial-mesenchymal transition induced by transforming growth factor B-1/Snail activation aggravates invasive growth of cholangiocarcinoma. Am J Pathol. 2010;177:141–52.PubMedPubMedCentralCrossRefGoogle Scholar
  25. 25.
    Boulter L, et al. WNT signaling drives cholangiocarcinoma growth and can be pharmacologically inhibited. J Clin Invest. 2015;125:1269–85.PubMedPubMedCentralCrossRefGoogle Scholar
  26. 26.
    Nakeeb A, Pitt HA, Sohn TA, et al. Cholangiocarcinoma. A spectrum of intrahepatic, perihilar, and distal tumors. Ann Surg. 1996;224(4):463.PubMedPubMedCentralCrossRefGoogle Scholar
  27. 27.
    Malaguarnera G, Paladina I, Giordano M, Malaguarnera M, Bertino G, Berretta M. Serum markers of intrahepatic cholangiocarcinoma. Dis Markers. 2013;34(4):219.PubMedPubMedCentralCrossRefGoogle Scholar
  28. 28.
    Kim HJ, Kim MH, Myung SJ, et al. A new strategy for the application of CA19-9 in the differentiation of pancreaticobiliary cancer: analysis using a receiver operating characteristic curve. Am J Gastroenterol. 1999;94(7):1941.PubMedCrossRefGoogle Scholar
  29. 29.
    Patel AH, Harnois DM, Klee GG, LaRusso NF, Gores GJ. The utility of CA 19-9 in the diagnoses of cholangiocarcinoma in patients without primary sclerosing cholangitis. Am J Gastroenterol. 2000;95(1):204.PubMedCrossRefGoogle Scholar
  30. 30.
    Siqueira E, Schoen RE, Silverman W, et al. Detecting cholangiocarcinoma in patients with primary sclerosing cholangitis. Gastrointest Endosc. 2002;56(1):40.PubMedCrossRefGoogle Scholar
  31. 31.
    Maeda T, Adachi E, Kajiyama K, Sugimachi K, Tsuneyoshi M. Combined hepatocellular and cholangiocarcinoma: proposed criteria according to cytokeratin expression and analysis of clinicopathologic features. Hum Pathol. 1995 Sep;26(9):956–64.PubMedCrossRefGoogle Scholar
  32. 32.
    Saini S. Imaging of the hepatobiliary tract. N Engl J Med. 1997;336(26):1889.PubMedCrossRefGoogle Scholar
  33. 33.
    Choi SH, Han JK, Lee JM, et al. Differentiating malignant from benign common bile duct stricture with multiphasic helical CT. Radiology. 2005;236(1):178. Epub 2005 Jun 13.PubMedCrossRefGoogle Scholar
  34. 34.
    Iavarone M, Piscaglia F, Vavassori S, et al. Contrast enhanced CT-scan to diagnose intrahepatic cholangiocarcinoma in patients with cirrhosis. J Hepatol. 2013;58(6):1188–93. Epub 2013 Feb 26.PubMedCrossRefGoogle Scholar
  35. 35.
    Adachi T, Eguchi S, Beppu T, et al. Prognostic impact of preoperative lymph node enlargement in intrahepatic cholangiocarcinoma: a multi-institutional study by the Kyushu Study Group of Liver Surgery. Ann Surg Oncol. 2015;22(7):2269–78. Epub 2015 Jan 13.PubMedCrossRefGoogle Scholar
  36. 36.
    Tillich M, Mischinger HJ, Preisegger KH, Rabl H, Szolar DH. Multiphasic helical CT in diagnosis and staging of hilar cholangiocarcinoma. AJR Am J Roentgenol. 1998;171(3):651.PubMedCrossRefGoogle Scholar
  37. 37.
    Manfredi R, Barbaro B, Masselli G, Vecchioli A, Marano P. Magnetic resonance imaging of cholangiocarcinoma. Semin Liver Dis. 2004;24(2):155.PubMedCrossRefGoogle Scholar
  38. 38.
    Pelsang RE, Johlin FC. A percutaneous biopsy technique for patients with suspected biliary or pancreatic cancer without a radiographic mass. Abdom Imaging. 1997;22(3):307.PubMedCrossRefGoogle Scholar
  39. 39.
    Corvera CU, Blumgart LH, Akhurst T, et al. 18F-fluorodeoxyglucose positron emission tomography influences management decisions in patients with biliary cancer. J Am Coll Surg. 2008;206(1):57. Epub 2007 Oct 1.PubMedCrossRefGoogle Scholar
  40. 40.
    Weber SM, RP DM, Fong Y, Blumgart LH, Jarnagin WR. Staging laparoscopy in patients with extrahepatic biliary carcinoma. Analysis of 100 patients. Ann Surg. 2002;235(3):392.PubMedPubMedCentralCrossRefGoogle Scholar
  41. 41.
    Su CH, Tsay SH, Wu CC, et al. Factors influencing postoperative morbidity, mortality, and survival after resection for hilar cholangiocarcinoma. Ann Surg. 1996;223(4):384.PubMedPubMedCentralCrossRefGoogle Scholar
  42. 42.
    Khan SA, et al. Guidelines for the diagnosis and treatment of cholangiocarcinoma: an update. Gut. 2012;61:1657–69.PubMedPubMedCentralCrossRefGoogle Scholar
  43. 43.
    Liberato MJ, Canena JM. Endoscopic stenting for hilar cholangiocarcinoma: efficacy of unilateral and bilateral placement of plastic and metal stents in a retrospective review of 480 patients. BMC Gastroenterol. 2012;12:103.PubMedPubMedCentralCrossRefGoogle Scholar
  44. 44.
    Tsao JI, Nimura Y, Kamiya J, et al. Management of hilar cholangiocarcinoma: comparison of an American and a Japanese experience. Ann Surg. 2000;232(2):166.PubMedPubMedCentralCrossRefGoogle Scholar
  45. 45.
    Edge SB, Byrd DR, Compton CC, et al., editors. American Joint Committee on Cancer staging manual. 7th ed. New York: Springer; 2010. p. 219.Google Scholar
  46. 46.
    Panjala C, Nguyen JH, Al-Hajjaj AN, et al. Impact of neoadjuvant chemoradiation on the tumor burden before liver transplantation for unresectable cholangiocarcinoma. Liver Transpl. 2012;18(5):594.PubMedCrossRefGoogle Scholar
  47. 47.
    Meyer CG, Penn I, James L. Liver transplantation for cholangiocarcinoma: results in 207 patients. Transplantation. 2000;69:1633–7.PubMedCrossRefGoogle Scholar
  48. 48.
    Croome KP, Rosen CB, Heimbach JK, Nagorney DM. Is liver transplantation appropriate for patients with potentially resectable De Novo hilar cholangiocarcinoma? J Am Coll Surg. 2015;221(1):130–9. Epub 2015 Mar 11.PubMedCrossRefGoogle Scholar
  49. 49.
    Rea DJ, Heimback JK, Rosen CB, et al. Ann Surg. 2005;242(3):451–8.PubMedPubMedCentralGoogle Scholar
  50. 50.
    Eckel F, Brunner T, Jelic S, ESMO Guidelines Working Group. Biliary cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2011;22(Suppl 6):vi40–4.PubMedGoogle Scholar
  51. 51.
    Neoptolemos JP, Moore MJ, Cox TF, et al. European Study Group for Pancreatic Cancer. Effect of adjuvant chemotherapy with fluorouracil plus folinic acid or gemcitabine vs observation on survival in patients with resected periampullary adenocarcinoma: the ESPAC-3 periampullary cancer randomized trial. JAMA. 2012;308(2):147.Google Scholar
  52. 52.
    Primrose JN, Fox R, Palmer DH, et al. Adjuvant capecitabine for biliary tract cancer: the BILCAP randomized study (abstract). J Clin Oncol. 2017; 35 (suppl; abstr 4006).CrossRefGoogle Scholar
  53. 53.
    Valle J, Wasan H, Palmer DH, et al. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med. 2010;362(14):1273.PubMedCrossRefGoogle Scholar
  54. 54.
    André T, Tournigand C, Rosmorduc O, et al. Gemcitabine combined with oxaliplatin (GEMOX) in advanced biliary tract adenocarcinoma: a GERCOR study. Ann Oncol. 2004;15(9):1339.PubMedCrossRefGoogle Scholar
  55. 55.
    Knox JJ, Hedley D, Oza A, et al. Combining gemcitabine and capecitabine in patients with advanced biliary cancer: a phase II trial. J Clin Oncol. 2005;23(10):2332.PubMedCrossRefGoogle Scholar
  56. 56.
    Novarino AM, Satolli MA, Chiappino I, et al. FOLFOX-4 regimen or single-agent gemcitabine as first-line chemotherapy in advanced biliary tract cancer. Am J Clin Oncol. 2013;36(5):466–71.PubMedCrossRefGoogle Scholar
  57. 57.
    Nehls O, Oettle H, Hartmann JT, et al. Capecitabine plus oxaliplatin as first-line treatment in patients with advanced biliary system adenocarcinoma: a prospective multicentre phase II trial. Br J Cancer. 2008;98(2):309. Epub 2008 Jan 8.PubMedPubMedCentralCrossRefGoogle Scholar
  58. 58.
    Zhu AX, Meyerhardt JA, Blaszkowsky LS, et al. Efficacy and safety of gemcitabine, oxaliplatin, and bevacizumab in advanced biliary-tract cancers and correlation of changes in 18-fluorodeoxyglucose PET with clinical outcome: a phase 2 study. Lancet Oncol. 2010;11(1):48–54. Epub 2009 Nov 20.PubMedCrossRefGoogle Scholar
  59. 59.
    Guion-Dusserre JF, Lorgis V, Vincent J, Bengrine L, Ghiringhelli F. FOLFIRI plus bevacizumab as a second-line therapy for metastatic intrahepatic cholangiocarcinoma. World J Gastroenterol. 2015;21(7):2096–101.PubMedPubMedCentralCrossRefGoogle Scholar
  60. 60.
    Philip PA, Mahoney MR, Allmer C, et al. Phase II study of erlotinib in patients with advanced biliary cancer. J Clin Oncol. 2006;24(19):3069.PubMedCrossRefGoogle Scholar
  61. 61.
    Lubner SJ, Mahoney MR, Kolesar JL, et al. Report of a multicenter phase II trial testing a combination of biweekly bevacizumab and daily erlotinib in patients with unresectable biliary cancer: a phase II Consortium study. J Clin Oncol. 2010;28(21):3491. Epub 2010 Jun 7.PubMedPubMedCentralCrossRefGoogle Scholar
  62. 62.
    McMasters KM, Tuttle TM, Leach SD, et al. Neoadjuvant chemoradiation for extrahepatic cholangiocarcinoma. Am J Surg. 1997;174(6):605.PubMedCrossRefGoogle Scholar
  63. 63.
    Nelson JW, Ghafoori AP, Willett CG, et al. Concurrent chemoradiotherapy in resected extrahepatic cholangiocarcinoma. Int J Radiat Oncol Biol Phys. 2009;73(1):148. Epub 2008 Sep 19.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  • Leonard M. Quinn
    • 1
  • Nicholas Bird
    • 1
  • Robert Jones
    • 2
  • David Vass
    • 1
  • Hassan Malik
    • 2
    Email author
  1. 1.Hepatobiliary Surgery, Digestive Diseases UnitAintree University HospitalLiverpoolUK
  2. 2.Department of Liver SurgeryAintree University Hospital NHS Foundation TrustLiverpoolUK

Personalised recommendations